Santi Barbera

2.4k total citations
17 papers, 978 citations indexed

About

Santi Barbera is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Santi Barbera has authored 17 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Santi Barbera's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Santi Barbera is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Santi Barbera collaborates with scholars based in Italy, United States and Malaysia. Santi Barbera's co-authors include Cesare Gridelli, Ciro Gallo, Francesco Perrone, Francesco Rosetti, Luigi Manzione, Sergio Robbiati, Paolo Maione, S. Cigolari, Elena Piazza and Luciano Frontini and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Santi Barbera

16 papers receiving 952 citations

Peers

Santi Barbera

ONCOL

PRM

SURGE

PHEOH

Francesco Rosetti Italy

Francovito Piantedosi Italy

Haa‐Na Song South Korea

Trevor A. Jolly United States

Juan Antonio Virizuela Spain

Olumide B. Gbolahan United States

Hans J.M. Smit Netherlands

Yutian Lai China

Véronique Girre France

Aart Beeker Netherlands

Francesco Rosetti Italy

Santi Barbera

640 ×1.0

ONCOL

437 ×1.0

PRM

149 ×1.0

139 ×1.2

SURGE

132 ×1.2

PHEOH

Citations per year, relative to Santi Barbera Santi Barbera (= 1×) peers Francesco Rosetti

Countries citing papers authored by Santi Barbera

Since Specialization

Citations

This map shows the geographic impact of Santi Barbera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Santi Barbera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Santi Barbera more than expected).

Fields of papers citing papers by Santi Barbera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Santi Barbera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Santi Barbera. The network helps show where Santi Barbera may publish in the future.

Co-authorship network of co-authors of Santi Barbera

This figure shows the co-authorship network connecting the top 25 collaborators of Santi Barbera. A scholar is included among the top collaborators of Santi Barbera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Santi Barbera. Santi Barbera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Morabito, Alessandro, Vittorio Gebbia, Saverio Cinieri, et al.. (2013). Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) 2: CAPPA-2 study.. Journal of Clinical Oncology. 31(15_suppl). 8066–8066.

Scagliotti, Giorgio V., P. Kosmidis, Filippo de Marinis, et al.. (2012). Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. Annals of Oncology. 23(8). 2082–2087. 27 indexed citations

Gridelli, Cesare, Andrea Ardizzoni, Sandro Barni, et al.. (2011). Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study. Lung Cancer. 74(3). 462–468. 13 indexed citations

Gridelli, Cesare, Ciro Gallo, Alessandro Morabito, et al.. (2011). Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial. Journal of Thoracic Oncology. 7(1). 233–242. 5 indexed citations

Maïo, Massimo Di, Alessandro Morabito, Santi Barbera, et al.. (2010). Education level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials.. Journal of Clinical Oncology. 28(15_suppl). 6124–6124. 1 indexed citations

Gridelli, Cesare, Ermelinda De Maio, Santi Barbera, et al.. (2008). The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. Lung Cancer. 61(1). 67–72. 8 indexed citations

Novello, Silvia, Paolo Bruzzi, A Masotti, et al.. (2007). Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Annals of Oncology. 18(5). 903–908. 15 indexed citations

Gridelli, Cesare, Ciro Gallo, Anna Ceribelli, et al.. (2007). Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. The Lancet Oncology. 8(6). 500–512. 79 indexed citations

Marinis, Filippo de, Fabrizio Nelli, Marco Lombardo, et al.. (2005). A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first‐line treatment in patients with poor‐prognosis small cell lung carcinoma. Cancer. 103(4). 772–779. 9 indexed citations

10.

Maïo, Massimo Di, Cesare Gridelli, Ciro Gallo, et al.. (2005). Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. The Lancet Oncology. 6(9). 669–677. 181 indexed citations

11.

Maione, Paolo, Francesco Perrone, Ciro Gallo, et al.. (2005). Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study. Journal of Clinical Oncology. 23(28). 6865–6872. 352 indexed citations

12.

Gridelli, Cesare, Ciro Gallo, Massimo Di Maïo, et al.. (2004). A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer. 91(12). 1996–2004. 143 indexed citations

13.

Maïo, Massimo Di, Cesare Gridelli, Ciro Gallo, et al.. (2004). Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. British Journal of Cancer. 90(12). 2288–2296. 102 indexed citations

14.

Gallelli, Luca, Marco Nardi, Santi Barbera, et al.. (2003). Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer. Pharmacological Research. 49(3). 259–263. 22 indexed citations

15.

Maïo, Massimo Di, Federica Perrone, Ciro Gallo, et al.. (2003). Supportive care in patients with advanced non-small-cell lung cancer. British Journal of Cancer. 89(6). 1013–1021. 19 indexed citations

16.

Marinis, Filippo de, Cesare Gridelli, Marco Lombardo, et al.. (2003). O-279 A multicenter randomised phase II study of cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as first line treatment in patients with small cell lung cancer (SCLC): Preliminary results. Lung Cancer. 41. S81–S82. 1 indexed citations

17.

Portalone, L, Andrea Altieri, Santi Barbera, et al.. (2001). Preventive epoetin a (EPO) use in the treatment of advanced nsclc: an AIPO oncology study group multicenter trial. European Journal of Cancer. 37. S56–S56. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact